Oregon Therapeutics
Pre-clinicalNew targeted therapy in Cancer “First in Class” & “Best in Class”Inhibition of Protein Disulfide IsomeraseOregon’s objective is to take this new drug candidate into clinical development.
Founded
2018
Focus
Small Molecules
About
New targeted therapy in Cancer “First in Class” & “Best in Class”Inhibition of Protein Disulfide IsomeraseOregon’s objective is to take this new drug candidate into clinical development.
Company Info
TypePrivate
Founded2018
LocationParis, France
StagePre-clinical
Contact
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile